RESUMEN
Background: Withaferin-A (WA), an active principle obtained from a traditional Indian herb known asAshwagandha or the Indian ginseng, has been shown to prevent and cure urethane-induced lung tumorsin mice, and also inhibit the growth of transplanted sarcoma in mice.Objectives: In this study, we evaluated the safety and pharmacokinetics of WA in patients with advancedstage high-grade osteosarcoma.Methods: A phase I dose escalation study was planned using the classical 3 þ 3 design (C33D). Doseescalation cohorts comprised of 72, 108, 144 and 216 mg of WA administered in two to four divided dosesper day. Three patients were enrolled in each cohort and the last patient was observed for at least 30 daysfor any dose-limiting toxicity before progressing to a higher cohort. Pharmacokinetic studies wereperformed using high performance liquid chromatography (HPLC) technique with sensitivity up to 50 ng/ml. Safety evaluation including clinical examination, detailed history of adverse events, Liver FunctionTests , Renal Function Tests and complete blood counts were performed at each visit. WA was administered daily till progression. Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 wasused for grading adverse events.Results: The formulation used was generally well tolerated. Eleven adverse events of grade 1 or grade 2severity were observed. No grade 3 or grade 4 adverse events were observed. Elevation of liver enzymes(5/11) and skin rash (2/11) was the most common adverse events. Other adverse effects include fatigue,fever, edema, and diarrhea (one each). None of the patients had detectable levels of WA in circulation.Conclusion: The formulation was well tolerated. However, WA appears to have low oral bioavailability.Further studies with improved formulations are warranted.© 2019 Transdisciplinary University, Bangalore and World Ayurveda Foundation. Publishing Services byElsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
RESUMEN
OBJECTIVE@#To investigate in-vivo anti-plasmodial activity of aqueous extracts of plants selected based on the symptomology mentioned in Ayurveda.@*METHODS@#The aqueous extracts of Holarrhena antidysentrica (H. antidysentrica) (Kutaja) and Azadirachta indica (A. indica) (Neemb) for their antiplasmodial potential in Plasmodium berghei (P. berghei) infected mice was assessed using Peters four day suppressive test. Both the extracts were administered at 2 dose levels, full dose (1 000 mg/d) and minimized dose (200 mg/d). 10(6)P. berghei infected RBCs were injected on day '0' and treated from day '0' till day '3' post-infection. Tail blood smears were collected, giemsa stained and analyzed. The mice were observed for survival and parasitemia was assessed till 50% of mice in control survived.@*RESULTS@#It was observed that the percentage of parasitemia increased gradually in all the groups, with maximum in control group (Day 3-35, Day 9-46.98) and minimum in Chloroquine arm (Day 3-14.06, Day 9-19.92). The percentage of parasitemia was compared using Mann-Whitney U test depicting that all test groups exhibited reduction in parasitemia as compared to control (P-value<0.002 for all groups). These groups showed similar percentage of survival as Chloroquine.@*CONCLUSIONS@#The present investigation demonstrated the anti-plasmodial effects of H. antidysentrica and A. indica, which are two most commonly used medicinal plants in Ayurved for treatment of fever.